Recent advances in systemic therapy for hepatocellular carcinoma
H Zhang, W Zhang, L Jiang, Y Chen - Biomarker Research, 2022 - Springer
Hepatocellular carcinoma (HCC) is one of the most common and lethal malignant tumors in
the world. Therapeutic options for advanced HCC are limited. Systemic treatment, especially …
the world. Therapeutic options for advanced HCC are limited. Systemic treatment, especially …
Function of the long noncoding RNAs in hepatocellular carcinoma: classification, molecular mechanisms, and significant therapeutic potentials
A Khan, X Zhang - Bioengineering, 2022 - mdpi.com
Hepatocellular carcinoma (HCC) is the most common and serious type of primary liver
cancer. HCC patients have a high death rate and poor prognosis due to the lack of clear …
cancer. HCC patients have a high death rate and poor prognosis due to the lack of clear …
Anticancer Drugs Compared to No Anticancer Drugs in Patients with Advanced Hepatobiliary Cancer: A Mapping Review and Evidence Gap Map
C Requeijo, J Bracchiglione, N Meza… - Clinical …, 2023 - Taylor & Francis
Introduction Despite being commonly recommended, the impact of anticancer drugs (ACDs)
on patient-important outcomes beyond survival for advanced hepatobiliary cancers (HBCs) …
on patient-important outcomes beyond survival for advanced hepatobiliary cancers (HBCs) …
[PDF][PDF] The potential prognostic novel markers PIV and PILE score to predict survival outcomes at hepatocellular cancer.
I Karadağ, S Karakaya, ME Yilmaz… - European Review for …, 2022 - europeanreview.org
OBJECTIVE: We aimed at investigating the prognostic significance of a novel immune
marker, PIV and PILE score (a score composite from PIV, LDH and ECOG PS), in patients …
marker, PIV and PILE score (a score composite from PIV, LDH and ECOG PS), in patients …
Systemic oncological treatments versus supportive care for patients with advanced Hepatobiliary Cancers: an overview of systematic reviews
J Bracchiglione, G Rodríguez-Grijalva, C Requeijo… - Cancers, 2023 - mdpi.com
Simple Summary Hepatobiliary cancers (that include hepatocellular carcinoma, intrahepatic
or extrahepatic cholangiocarcinoma and gallbladder cancer) are usually treated with …
or extrahepatic cholangiocarcinoma and gallbladder cancer) are usually treated with …
Is there still a place for tyrosine kinase inhibitors for the treatment of hepatocellular carcinoma at the time of immunotherapies? A focus on lenvatinib
M Decraecker, C Toulouse, JF Blanc - Cancers, 2021 - mdpi.com
Simple Summary The combination of atezolizumab and bevacizumab has changed the
therapeutic algorithm of advanced hepatocellular carcinomas. Therefore, the place of …
therapeutic algorithm of advanced hepatocellular carcinomas. Therefore, the place of …
Sequencing of systemic therapy in unresectable hepatocellular carcinoma: A systematic review and Bayesian network meta-analysis of randomized clinical trials
Q Wang, J Yu, X Sun, J Li, S Cao, Y Han… - Critical Reviews in …, 2024 - Elsevier
Purpose For patients with advanced or unresectable hepatocellular carcinoma (HCC), safe
and effective therapies are urgently needed to improve their long-term prognosis. Although …
and effective therapies are urgently needed to improve their long-term prognosis. Although …
Decoding the Mechanism of drugs of heterocyclic nature against hepatocellular carcinoma
Objectives: Hepatocellular carcinoma (HCC) is the sixth most common type of cancer and
accounts for~ 90% of cases, with an approximated incidence of> 1 million cases by 2025 …
accounts for~ 90% of cases, with an approximated incidence of> 1 million cases by 2025 …
AGA technical review on systemic therapies for hepatocellular carcinoma
We conducted a systematic review and reported it according to the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses statement. 8 The Technical Review Panel …
Items for Systematic Reviews and Meta-Analyses statement. 8 The Technical Review Panel …
[HTML][HTML] A patient-derived HCC spheroid system to model the tumor microenvironment and treatment response
E Crouchet, N Almeida, SC Durand, M Parnot… - JHEP Reports, 2025 - Elsevier
Background & Aims Hepatocellular carcinoma (HCC) is the third-leading and fastest rising
cause of cancer-related death worldwide. The discovery and preclinical development of …
cause of cancer-related death worldwide. The discovery and preclinical development of …